Role of IL-4 and Th2 responses in allograft rejection and tolerance
- PMID: 19337141
- DOI: 10.1097/MOT.0b013e32831ebdf5
Role of IL-4 and Th2 responses in allograft rejection and tolerance
Abstract
Purpose of review: Due to the dominance of Th1 cytokines in rejection and the ability of Th2 cytokines, particularly IL-4, to inhibit Th1 responses, it has long been held that Th2 cytokines can improve transplant outcomes. Although there is some support for this, there is mounting evidence that IL-4 and Th2 cytokines can promote graft dysfunction. These disparate effects are reviewed.
Recent findings: The role of Th2 cytokines in graft dysfunction is not necessarily due to promotion of humoral immunity, but is due to their ability to drive T-cell and non-T-cell responses including alternative activation of macrophages. Alternatively, activated macrophages compete with classically activated macrophages for arginine and they are mutually exclusive, analogous to mutual competition between Th1 and Th2 cells. Recent findings also point to two subsets of regulatory T cells (Tregs), each dependent on either Th1 or Th2 cytokines. In addition to its effects on bone marrow-derived cells, IL-4 affects parenchymal cells by signalling through the type II receptor, which consists of the IL-4R alpha chain (IL-4Ralpha) and the IL-13Ralpha1, which also binds IL-13.
Summary: The effects of Th2 cytokines in transplantation depend on their cellular targets, the timing and form of administration and on Th2 cytokine-dependent Tregs.
Similar articles
-
Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance.Curr Opin Organ Transplant. 2010 Aug;15(4):411-5. doi: 10.1097/MOT.0b013e32833b7929. Curr Opin Organ Transplant. 2010. PMID: 20613526 Review.
-
IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation.Transpl Immunol. 2007 Apr;17(3):178-86. doi: 10.1016/j.trim.2006.09.035. Epub 2006 Nov 3. Transpl Immunol. 2007. PMID: 17331844
-
Th1 to Th2 immune deviation facilitates, but does not cause, islet allograft tolerance in mice.Cytokine. 2010 Sep;51(3):311-9. doi: 10.1016/j.cyto.2010.06.007. Epub 2010 Jul 2. Cytokine. 2010. PMID: 20598563
-
Role of TH1/TH2 cytokines in kidney allograft rejection.Transplant Proc. 2008 Dec;40(10):3390-2. doi: 10.1016/j.transproceed.2008.07.125. Transplant Proc. 2008. PMID: 19100396
-
CD4(+) T-cell subsets in transplantation.Immunol Rev. 2013 Mar;252(1):183-91. doi: 10.1111/imr.12038. Immunol Rev. 2013. PMID: 23405905 Review.
Cited by
-
Sterile inflammation in thoracic transplantation.Cell Mol Life Sci. 2021 Jan;78(2):581-601. doi: 10.1007/s00018-020-03615-7. Epub 2020 Aug 17. Cell Mol Life Sci. 2021. PMID: 32803398 Free PMC article. Review.
-
Integrated Proteome and Cytokine Profiles Reveal Ceruloplasmin Eliciting Liver Allograft Tolerance via Antioxidant Cascades.Front Immunol. 2018 Sep 26;9:2216. doi: 10.3389/fimmu.2018.02216. eCollection 2018. Front Immunol. 2018. PMID: 30319655 Free PMC article.
-
SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.Cell Mol Immunol. 2012 Sep;9(5):390-8. doi: 10.1038/cmi.2012.28. Epub 2012 Aug 27. Cell Mol Immunol. 2012. PMID: 22922441 Free PMC article.
-
Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue.J Immunol Regen Med. 2018 Mar;1:1-12. doi: 10.1016/j.regen.2018.01.003. Epub 2018 Feb 22. J Immunol Regen Med. 2018. PMID: 29869643 Free PMC article.
-
An Immune Atlas of T Cells in Transplant Rejection: Pathways and Therapeutic Opportunities.Transplantation. 2023 Nov 1;107(11):2341-2352. doi: 10.1097/TP.0000000000004572. Epub 2023 Oct 21. Transplantation. 2023. PMID: 37026708 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials